Tivantinib in Treating Patients With Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 11, 2012

Primary Completion Date

August 18, 2015

Study Completion Date

August 18, 2015

Conditions
Hormone-Resistant Prostate CancerProstate AdenocarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Optional correlative studies

OTHER

Placebo

Given PO

DRUG

Tivantinib

Given PO

Trial Locations (20)

14263

Roswell Park Cancer Institute, Buffalo

20007

MedStar Georgetown University Hospital, Washington D.C.

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

21204

University of Maryland Saint Joseph Medical Center, Towson

33612

Moffitt Cancer Center, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

44106

Case Western Reserve University, Cleveland

44195

Cleveland Clinic Foundation, Cleveland

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

46804

Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard, Fort Wayne

53792

University of Wisconsin Hospital and Clinics, Madison

60201

NorthShore University HealthSystem-Evanston Hospital, Evanston

60426

Ingalls Memorial Hospital, Harvey

60611

Northwestern University, Chicago

60616

Michael Reese Hospital, Chicago

60637

University of Chicago Comprehensive Cancer Center, Chicago

61615

Illinois CancerCare-Peoria, Peoria

62526

Decatur Memorial Hospital, Decatur

62702

Southern Illinois University School of Medicine, Springfield

63141

Mercy Hospital Saint Louis, St Louis

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01519414 - Tivantinib in Treating Patients With Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter